Fulgent Genetic (NASDAQ:FLGT) posted its quarterly earnings results on Monday. The company reported $0.02 earnings per share for the quarter, hitting the consensus estimate of $0.02, Bloomberg Earnings reports. The company had revenue of $4.64 million for the quarter, compared to the consensus estimate of $5.03 million. Fulgent Genetic had a negative return on equity of 0.02% and a negative net margin of 0.42%.

Fulgent Genetic (NASDAQ:FLGT) traded up 10.1967% during mid-day trading on Wednesday, hitting $5.9396. The company had a trading volume of 33,210 shares. The company has a 50 day moving average of $6.44 and a 200 day moving average of $9.15. Fulgent Genetic has a 1-year low of $4.49 and a 1-year high of $13.90. The firm’s market capitalization is $105.08 million.

In other Fulgent Genetic news, insider Ming Hsieh acquired 20,000 shares of Fulgent Genetic stock in a transaction that occurred on Thursday, June 15th. The stock was bought at an average price of $5.26 per share, with a total value of $105,200.00. Following the completion of the purchase, the insider now directly owns 6,482,244 shares of the company’s stock, valued at approximately $34,096,603.44. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Several research firms recently weighed in on FLGT. Credit Suisse Group cut their price target on Fulgent Genetic from $11.00 to $10.00 and set an “outperform” rating on the stock in a research note on Tuesday. Zacks Investment Research upgraded Fulgent Genetic from a “sell” rating to a “hold” rating in a research note on Monday, July 10th.

TRADEMARK VIOLATION NOTICE: “Fulgent Genetic (NASDAQ:FLGT) Posts Quarterly Earnings Results, Hits Expectations” was posted by Daily Political and is owned by of Daily Political. If you are viewing this story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The correct version of this story can be read at https://www.dailypolitical.com/2017/08/09/fulgent-genetic-nasdaqflgt-posts-quarterly-earnings-results-hits-expectations.html.

Fulgent Genetic Company Profile

Fulgent Genetics, Inc is a technology company. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. The Company has developed a technology platform that integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes.

Receive News & Ratings for Fulgent Genetic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulgent Genetic and related companies with MarketBeat.com's FREE daily email newsletter.